GlobeNewswire Inc.··Researchandmarkets.ComRoche's OCREVUS Hits $7.6B in Sales as MS Drug Fends Off Biosimilar Threats
Roche's OCREVUS reached $7.6B in 2024 sales, up 9% YoY, driven by new subcutaneous formulation and strong efficacy data across MS types.
RHHBYbiosimilar competitionmultiple sclerosis